Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04336241
Title Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Replimune Inc.
Indications

esophageal cancer

gastrointestinal system cancer

gastroesophageal junction adenocarcinoma

hepatocellular carcinoma

lung cancer

breast cancer

Advanced Solid Tumor

uveal melanoma

colorectal cancer

stomach cancer

Therapies

Nivolumab + RP2

RP2

Age Groups: adult | senior
Covered Countries ESP


No variant requirements are available.